Black Diamond Therapeutics, Inc. (BDTX) — Stock Score Summary

Black Diamond Therapeutics, Inc. (BDTX) has a MoatMap StockRank of 16/100 based on Quality (43/100), Value (38/100), and Momentum (19/100) factor scores. The current signal is STRONG SELL. Black Diamond Therapeutics is a clinical-stage oncology company. It lacks commercialized assets, pricing power, and predictable cash flows, making it too speculative for our concentrated portfolio.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing precision medicines for cancer patients with genetically defined mutations. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) platform to discover and develop novel allosteric and mutation-specific therapies for historically undruggable cancer targets. Black Diamond is a niche biotechnology firm focused on addressing high unmet medical needs in precision oncology.

Key Financial Metrics

Price$1.90
Market Cap$129M
P/E (Forward)-1.80
Price/Book1.15
Return on Equity-35.2%
Return on Invested Capital15.6%
Debt/Equity17.14
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-26M

Black Diamond Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Black Diamond Therapeutics, Inc.’s (BDTX) StockRank?
MoatMap’s StockRank for Black Diamond Therapeutics, Inc. (BDTX) is 16/100, with a Strong Sell signal. It is a composite of Quality (43), Value (38), and Momentum (19) factor ranks across MoatMap’s 19,000+ stock universe.
Does Black Diamond Therapeutics, Inc. have an economic moat?
Black Diamond Therapeutics, Inc. (BDTX) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Black Diamond Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Black Diamond Therapeutics, Inc. (BDTX) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Black Diamond Therapeutics, Inc. in?
Black Diamond Therapeutics, Inc. (BDTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksBDTX deep dive reportAI ChampionsHow we score stocksSense-check another stock